ArticleEuropean journal of human genetics : EJHG2014
Life insurance: genomic stratification and risk classification.
Article in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends on fears and concerns of genetic discrimination: a systematic literature review.Journal of human genetics · 2016Pooled it
- Attitude Disparity and Worrying Scenarios in Genetic Discrimination-Based on Questionnaires from China.Healthcare (Basel, Switzerland) · 2023Article
- Restricted access data in the neurosciences: Are the restrictions always justified?Frontiers in neuroscience · 2022Article
- Genetic discrimination: introducing the Asian perspective to the debate.NPJ genomic medicine · 2021Review
- Study protocol: the Australian genetics and life insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project.BMC medical ethics · 2021Article
- How are genetic test results being used by Australian life insurers?European journal of human genetics : EJHG · 2018Article
- Hypertension genomics and cardiovascular prevention.Annals of translational medicine · 2018Review
- Tensions in ethics and policy created by National Precision Medicine Programs.Human genomics · 2018Article
- On the readiness of physicians for pharmacogenomics testing: an empirical assessment.The pharmacogenomics journal · 2018Article
- Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers.Frontiers in genetics · 2017Article
- Genetic discrimination legislation in Canada: moving from rhetoric to real debate.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016Article
- Epigenome data release: a participant-centered approach to privacy protection.Genome biology · 2015Article
- Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections.Journal of genetic counseling · 2015Article
- The Human Genome Project, and recent advances in personalized genomics.Risk management and healthcare policy · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
With the development and increasing accessibility of new genomic tools such as next-generation sequencing, genome-wide association studies, and genomic stratification models, the debate on genetic discrimination in the context of life insurance became even more complex, requiring a review of current practices and the exploration of new scenarios. In this perspective, a multidisciplinary group of international experts representing different interests revisited the genetics and life insurance debate during a 2-day symposium 'Life insurance: breast cancer research and genetic risk prediction seminar' held in Quebec City, Canada on 24 and 25 September 2012. Having reviewed the current legal, social, and ethical issues on the use of genomic information in the context of life insurance, the Expert Group identified four main questions: (1) Have recent developments in genomics and related sciences changed the contours of the genetics and life insurance debate? (2) Are genomic results obtained in a research context relevant for life insurance underwriting? (3) Should predictive risk assessment and risk stratification models based on genomic data also be used for life insurance underwriting? (4) What positive actions could stakeholders in the debate take to alleviate concerns over the use of genomic information by life insurance underwriters? This paper presents a summary of the discussions and the specific action items recommended by the Expert Group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.